Alan Auerbach Sells 16,938 Shares of Puma Biotechnology (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan Auerbach sold 16,938 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $5.84, for a total transaction of $98,917.92. Following the transaction, the chief executive officer owned 7,163,963 shares in the company, valued at $41,837,543.92. The trade was a 0.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Puma Biotechnology Stock Up 1.8%

Shares of NASDAQ:PBYI traded up $0.11 during trading on Thursday, reaching $6.20. The stock had a trading volume of 374,316 shares, compared to its average volume of 344,360. The stock has a market cap of $312.42 million, a P/E ratio of 8.38 and a beta of 1.19. The business has a fifty day moving average price of $5.42 and a 200-day moving average price of $4.77. Puma Biotechnology, Inc. has a fifty-two week low of $2.58 and a fifty-two week high of $6.29.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.12. The company had revenue of $54.48 million during the quarter, compared to the consensus estimate of $51.00 million. Puma Biotechnology had a net margin of 17.45% and a return on equity of 36.17%. As a group, equities analysts forecast that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Institutional Investors Weigh In On Puma Biotechnology

Large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. lifted its position in shares of Puma Biotechnology by 4,823,365.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock worth $5,123,000 after purchasing an additional 964,673 shares during the last quarter. LSV Asset Management increased its position in Puma Biotechnology by 903.3% in the 2nd quarter. LSV Asset Management now owns 535,740 shares of the biopharmaceutical company’s stock worth $1,838,000 after buying an additional 482,340 shares during the period. Ritholtz Wealth Management increased its position in Puma Biotechnology by 139.0% in the 3rd quarter. Ritholtz Wealth Management now owns 470,767 shares of the biopharmaceutical company’s stock worth $2,500,000 after buying an additional 273,782 shares during the period. Bridgeway Capital Management LLC lifted its holdings in shares of Puma Biotechnology by 113.8% during the third quarter. Bridgeway Capital Management LLC now owns 433,561 shares of the biopharmaceutical company’s stock worth $2,302,000 after buying an additional 230,771 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Puma Biotechnology by 16.8% in the second quarter. American Century Companies Inc. now owns 1,342,275 shares of the biopharmaceutical company’s stock valued at $4,604,000 after acquiring an additional 192,615 shares during the period. Institutional investors own 61.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Weiss Ratings cut shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Wall Street Zen downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.